Cero Therapeutics HOLDINGS, Inc. (CERO) intrinsic value & 10-year financials
Cero Therapeutics HOLDINGS, Inc. (CERO) has no Graham intrinsic value right now because the formula needs positive earnings.
- Graham intrinsic value
- —
- Share price (Oct 17, 2026)
- $0.01
- Market cap
- $37
- Revenue (FY2025)
- —
- ROIC (10-yr avg)
- 26.3%
- Free cash flow (FY2025)
- —
CERO 10-year financial history
| Fiscal year | Revenue | Net income | EPS (diluted) | Free cash flow | Operating margin | ROIC |
|---|---|---|---|---|---|---|
| FY2025 | — | -$19.9M | — | — | — | — |
| FY2024 | — | — | — | — | — | — |
| FY2023 | — | -$2.5M | -$1,248.64 | — | — | 25.2% |
| FY2022 | — | -$667.7K | — | — | — | 27.5% |
| FY2021 | — | — | — | — | — | — |
Source: annual 10-K filings on SEC EDGAR. Figures in USD.
Executive summary
CERO THERAPEUTICS HOLDINGS, INC. revenue growth over the past decade is N/A; insufficient history prevents a reliable 10-year CAGR calculation.
CERO THERAPEUTICS HOLDINGS, INC. has earned high returns on invested capital, averaging 26.3% ROIC over the available history. High ROIC is consistent with a durable franchise, but it is not by itself proof of an economic moat.
CERO THERAPEUTICS HOLDINGS, INC. capital allocation metrics are N/A for the decade; share count and net debt history are incomplete.
Benjamin Graham lens
CERO THERAPEUTICS HOLDINGS, INC. is evaluated under Benjamin Graham's defensive framework using SEC EDGAR fundamentals using an 8.5 + 2g earnings multiple and a 5.1% AAA bond-yield baseline.